| Children's Mercy Home Care | |
| 700 Nw Argosy Parkway, Suite 200, Riverside, Missouri 64150 | |
| (816) 701-4300 | |
| Not Available |
| Name | Children's Mercy Home Care |
|---|---|
| Location | 700 Nw Argosy Parkway, Suite 200, Riverside, Missouri |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services |
| Medicare ID | 267618 |
| Ownership Type | Voluntary Non-profit - Other |
| Service Area Zip Codes |
| NPI Number | 1144462029 |
| Organization Name | THE CHILDREN'S MERCY HOSPITAL |
| Doing Business As | CHILDREN'S MERCY HOME CARE |
| Address | 700 Nw Argosy Pkwy Ste 200, Riverside, MO 64150 |
| Phone Number | 816-895-5000 |
News Archive
Tri Hospital MRI Center of Port Huron, Michigan has selected Merge Healthcare to provide a radiology information system (RIS) that includes integrated business workflow from scheduling through billing.
Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
Scientists who fed a cocktail of key amino acids to mice improved sleep disturbances caused by brain injuries in the animals. These new findings suggest a potential dietary treatment for millions of people affected by traumatic brain injury (TBI)—a condition that is currently untreatable.
› Verified 5 days ago
| Quality Rating: | Not Available* |
| * This measure currently does not have data or provider has been certified/recertified for less than 6 months. | |
News Archive
Tri Hospital MRI Center of Port Huron, Michigan has selected Merge Healthcare to provide a radiology information system (RIS) that includes integrated business workflow from scheduling through billing.
Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
Scientists who fed a cocktail of key amino acids to mice improved sleep disturbances caused by brain injuries in the animals. These new findings suggest a potential dietary treatment for millions of people affected by traumatic brain injury (TBI)—a condition that is currently untreatable.
› Verified 5 days ago
News Archive
Tri Hospital MRI Center of Port Huron, Michigan has selected Merge Healthcare to provide a radiology information system (RIS) that includes integrated business workflow from scheduling through billing.
Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.
Scientists who fed a cocktail of key amino acids to mice improved sleep disturbances caused by brain injuries in the animals. These new findings suggest a potential dietary treatment for millions of people affected by traumatic brain injury (TBI)—a condition that is currently untreatable.
› Verified 5 days ago
Children's Mercy Home Care Location: 700 Nw Argosy Parkway, Suite 200, Riverside, Missouri 64150 Ratings: NA Phone: (816) 701-4300 |